‘Encouraging’ ELATIVE data for elafibranor may spark race for primary biliary cholangitis

Key takeaways:Topline findings from the phase 3 ELATIVE trial showed that elafibranor improved cholestasis response in patients with primary biliary cholangitis, Ipsen and Genfit announced.Elafibranor, an investigational dual peroxisome activated receptor agonist, was granted breakthrough therapy designation by the FDA in 2019 for adults with primary biliary cholangitis disease who are intolerant, or have had an inadequate response, to ursodeoxycholic acid (UDCA).Given the recent setback for rival Intercept’s Ocaliva in pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis,Read More